Mankind Pharma 从武田制药公司获得酸性药物 Vonoprazan 在印度进行商业化许可。 Mankind Pharma licenses acidity drug Vonoprazan from Takeda Pharmaceuticals for commercialization in India.

Mankind Pharma 与武田制药签署非独家专利许可协议，在印度商业化酸性药物 Vonoprazan。 Mankind Pharma signs non-exclusive patent licensing deal with Takeda Pharmaceuticals to commercialize acidity drug Vonoprazan in India. 沃诺拉赞 (Vonoprazan) 是一种钾竞争性酸阻滞剂 (P-CAB)，用于治疗胃食管反流病 (GERD) 等酸相关疾病。 Vonoprazan, a potassium-competitive acid blocker (P-CAB), treats acid-related disorders such as Gastroesophageal Reflux Disease (GERD). Mankind Pharma 旨在通过这种创新治疗方法满足重大医疗需求并改善患者的健康状况。 Mankind Pharma aims to address a significant medical need and improve patients' health outcomes with this innovative treatment.

文章

Financial Express

Business Standard

The Economic Times

-- 显示更少 --

延伸阅读

相关故事